Milestone Pharmaceuticals Inc. (MIST)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. This filer's financial year end could not be read from its revenue history, so quarters are labelled by the calendar. Amounts in USD.

Revenue TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Gross Profit TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income TTM

-90M -60M -30M 0 30M 60M 90M Q4 '18: -23.8M Q1 '19: -30.5M Q2 '19: -41.2M Q3 '19: -49.1M Q4 '19: -57.9M Q1 '20: -63.7M Q2 '20: -62.5M Q3 '20: -60.8M Q4 '20: -50.7M Q1 '21: -46.5M Q2 '21: -32.7M Q3 '21: -34.9M Q4 '21: -43.1M Q1 '22: -44.5M Q2 '22: -62M Q3 '22: -62.8M Q4 '22: -59.6M Q1 '23: -61.1M Q2 '23: -60.7M Q3 '23: -61.1M Q4 '23: -61.1M Q1 '24: -56.1M Q2 '24: -49.3M Q3 '24: -43.6M Q4 '24: -42.1M Q1 '25: -52.1M Q2 '25: -55M Q3 '25: -57.2M Q4 '25: -62.1M Q1 '26: -65.3M Q2 '26: -78.4M Q2 '19 Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Net Income TTM

-90M -60M -30M 0 30M 60M 90M Q4 '18: -23.2M Q1 '19: -29.5M Q2 '19: -39.5M Q3 '19: -46.7M Q4 '19: -55.2M Q1 '20: -61.1M Q2 '20: -60.4M Q3 '20: -59.6M Q4 '20: -50M Q1 '21: -46.1M Q2 '21: -32.4M Q3 '21: -34.6M Q4 '21: -42.9M Q1 '22: -44.3M Q2 '22: -61.8M Q3 '22: -62.1M Q4 '22: -58.4M Q1 '23: -59.3M Q2 '23: -58.7M Q3 '23: -59.3M Q4 '23: -59.7M Q1 '24: -55.1M Q2 '24: -48.4M Q3 '24: -42.8M Q4 '24: -41.5M Q1 '25: -51.9M Q2 '25: -55.5M Q3 '25: -58M Q4 '25: -63.1M Q1 '26: -68.4M Q2 '26: -84M Q2 '19 Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Cost of Revenue TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow TTM

-75M -50M -25M 0 25M 50M 75M Q4 '18: -21M Q1 '19: -31.1M Q2 '19: -39.2M Q3 '19: -41.9M Q4 '19: -51.2M Q1 '20: -54.5M Q2 '20: -59.5M Q3 '20: -58.6M Q4 '20: -50.7M Q1 '21: -45.1M Q2 '21: -27.5M Q3 '21: -29.6M Q4 '21: -33.2M Q1 '22: -34.7M Q2 '22: -49.8M Q3 '22: -52M Q4 '22: -52.5M Q1 '23: -52.4M Q2 '23: -48.9M Q3 '23: -49.5M Q4 '23: -46.4M Q1 '24: -41.5M Q2 '24: -36.9M Q3 '24: -31.8M Q4 '24: -28.8M Q1 '25: -33.9M Q2 '25: -40.4M Q3 '25: -43.1M Q4 '25: -49M Q1 '26: -51.1M Q2 '26: -61.3M Q2 '19 Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Free Cash Flow TTM

-75M -50M -25M 0 25M 50M 75M Q4 '18: -21.1M Q2 '23: -49.2M Q3 '23: -49.7M Q4 '23: -46.5M Q2 '25: -40.4M Q3 '25: -43.1M Q4 '25: -49.3M Q1 '26: -51.5M Q2 '26: -61.6M Q4 '18 Q3 '23 Q2 '25 Q4 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

EPS TTM

-35.00 0.00 35.00 70.00 105.00 Q4 '18: 72.65 Q1 '19: 70.90 Q2 '19: 82.57 Q3 '19: 102.21 Q4 '20: -1.73 Q1 '21: -1.36 Q2 '21: -0.81 Q3 '21: -0.75 Q4 '21: -1.02 Q1 '22: -1.05 Q2 '22: -1.46 Q3 '22: -1.46 Q4 '22: -1.37 Q1 '23: -1.39 Q2 '23: -1.37 Q3 '23: -1.38 Q4 '23: -1.39 Q1 '24: -1.25 Q2 '24: -1.02 Q3 '24: -0.81 Q4 '24: -0.68 Q1 '25: -0.78 Q2 '25: -0.84 Q3 '25: -0.82 Q4 '25: -0.78 Q1 '26: -0.67 Q2 '26: -0.68 Q2 '19 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.